CION Ameerpet
Hormone therapy is associated with a small increase in ovarian cancer risk — small enough that for most women it is not the deciding factor, and it should be weighed against real benefits rather than treated as a reason to suffer.
Reporting on hormone therapy and cancer is dominated by relative risk, which is the number that makes headlines and the number that misleads. A stated percentage increase sounds alarming without any reference to what it is increasing from — and for ovarian cancer, the baseline is low.
General population lifetime ovarian cancer risk is roughly one to two per cent. A modest relative increase applied to a figure that small produces a modest absolute increase. The way to think about it is in terms of how many additional women out of a large number would be affected, which is a very different mental picture from a percentage.
There is a second point that gets lost. The evidence here is largely observational rather than from randomised trials, which means it establishes an association rather than proving causation. Women who take hormone therapy differ from those who do not in ways that are hard to fully adjust for. The association is consistent enough to take seriously and to mention in a discussion — it is not strong enough to make hormone therapy an unreasonable choice.
Roughly 1-2% lifetime risk in the general population. A modest relative increase on that stays modest in absolute terms.
A percentage increase with no baseline attached tells you almost nothing about your actual situation.
It establishes an association rather than proving causation. Enough to mention; not enough to decide for you.
The hormone therapy conversation is completely different after risk-reducing surgery. For a woman who has had her ovaries and tubes removed because of a BRCA variant, before the natural age of menopause, hormone therapy up to around that natural age is generally considered appropriate — it replaces hormones her body would still have been producing, rather than adding hormones beyond the normal span. And it cannot meaningfully raise her ovarian cancer risk, because the tissue that would have given rise to that cancer has been removed. The reasoning that applies at 55 does not apply at 38 after surgery. Source: NCCN Genetic/Familial High-Risk Assessment guidelines.
A risk figure on its own is not a decision. This is what actually sits on each side of the scale.
It is the most effective treatment available for hot flushes and night sweats, which for some women are genuinely debilitating rather than a minor inconvenience. It treats vaginal dryness and the discomfort during intercourse that many women endure silently for years. It improves sleep and mood where those are driven by menopausal change. And it protects bone density, which matters considerably for women who go through menopause early.
A small absolute increase in ovarian cancer risk, on a low baseline, from observational evidence. Separately, a small increase in breast cancer risk with combined preparations, which matters more for some women — particularly BRCA carriers — and which is often the more relevant consideration of the two. Both are real and both are worth discussing. Neither is a reason to endure severe symptoms without a conversation.
This is not one question with one answer. Where you sit changes the reasoning substantially.
For most women in this position, the ovarian cancer association is not the deciding factor. The absolute increase is small, the baseline is low, and the benefits of treating genuinely disruptive symptoms are immediate and substantial.
The usual approach is the lowest effective dose for as long as it is needed, with periodic review rather than an arbitrary stopping point. Where symptoms are primarily vaginal, local vaginal oestrogen treats them effectively with minimal systemic absorption, which sidesteps much of this discussion entirely.
Here the calculation shifts, and it is worth discussing with a specialist rather than resolving from a webpage. A carrier already has substantially elevated ovarian cancer risk, so a further increase operates on a higher baseline than it would in the general population.
In practice, this situation frequently prompts the more useful conversation: whether the time has come for risk-reducing surgery, which addresses the ovarian risk directly and then changes the hormone therapy question entirely. See risk-reducing surgery.
This is the situation where hormone therapy is most clearly appropriate, and it is frequently misunderstood by women who have read general warnings. Removing the ovaries at 38 causes an abrupt menopause more than a decade early, with real consequences for bone and cardiovascular health if untreated.
Hormone therapy up to around the natural age of menopause replaces what the body would otherwise still be producing. It does not meaningfully raise ovarian cancer risk, because the tissue at risk has been removed. This should be planned before the operation rather than raised once symptoms have started.
This is considerably more complex than the ovarian question and needs individual specialist advice rather than a general answer. Where breast cancer has been hormone-receptor-positive, systemic hormone therapy is usually avoided and non-hormonal approaches to menopausal symptoms are explored first.
This applies even after risk-reducing surgery, where the picture would otherwise be straightforward — it is one of the clearest examples of why breast and ovarian risk need discussing together rather than in separate clinics. See the BRCA breast-ovarian link.
Where the troublesome symptoms are vaginal dryness, discomfort during intercourse and associated urinary symptoms, local vaginal oestrogen is highly effective and involves minimal systemic absorption. Much of the systemic risk discussion simply does not apply.
This is worth knowing because a great many women endure these symptoms for years, either assuming nothing can be done or having read warnings about hormone therapy that do not apply to the local preparations. See pain during sex.
Women frequently arrive concerned about the ovarian association when the breast cancer association is the more relevant consideration for their situation, particularly with combined preparations containing a progestogen and particularly for BRCA carriers.
This is not a reason to avoid hormone therapy, but it is a reason to have the conversation properly rather than focusing on whichever risk you happened to read about. A good discussion covers both alongside the benefits, and reaches a decision rather than a vague unease.
These warrant assessment regardless of whether you take hormone therapy.
Bleeding after menopause always warrants prompt assessment, and unscheduled bleeding on HRT is not simply attributed to the hormones.
New within the past year and present on more than 12 days a month. See persistent bloating.
Early satiety — unable to finish meals you managed easily six months ago.
A dull ache present most days rather than an intermittent cramp. Persistence matters more than severity.
Report promptly regardless of hormone therapy, and continue any breast screening you are due.
Losing weight without trying always warrants assessment, whatever else is going on.
Unscheduled bleeding on hormone therapy is investigated in the same way as any other post-menopausal bleeding, rather than assumed to be a side effect.
Menopausal symptoms are real and treatable, and bone health matters. Neither should be sacrificed to a small risk increase without someone laying out both sides.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Genetic counselling is in-house at CION if your family history is part of the question.
A great many women stop hormone therapy, or never start it, on the strength of a headline — and then spend years with symptoms that were entirely treatable. That is a real harm, and it rarely gets counted, because nobody records the cost of a decision made on incomplete information.
Your first consultation at CION is free and runs to about 45 minutes. What is usually useful is not a risk figure but the context around it: what your baseline actually is, whether your family history changes it, whether your symptoms are systemic or local, and whether the breast association is more relevant to you than the ovarian one. That is a conversation, and it reaches a decision rather than a vague unease.
Where your family history warrants it, genetic counselling and BRCA and HRD testing are delivered in-house at CION. Where risk-reducing surgery is in the picture, the hormone therapy plan should be agreed before the operation rather than afterwards. Risk-reducing and gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there.
Free and unhurried. Long enough to weigh both sides properly rather than quote one number.
Untreated menopausal symptoms and bone loss are real harms. They belong on the scale alongside the risk.
Vaginal oestrogen treats vaginal symptoms effectively with minimal systemic absorption, sidestepping much of this discussion.
Where family history is part of the question, assessment and testing happen here rather than across referrals.
A rough guide to how the reasoning shifts. None of these replaces individual advice.
| Your situation | How the ovarian association weighs | Usual approach |
|---|---|---|
| Natural menopause, no family history | Small absolute increase on a low baseline. | Usually not the deciding factor. Lowest effective dose, reviewed periodically. |
| Vaginal symptoms only | Largely does not apply. | Local vaginal oestrogen, with minimal systemic absorption. |
| BRCA carrier, ovaries in place | Operates on an already raised baseline. | Discuss with a specialist; often prompts the risk-reducing surgery conversation. |
| After risk-reducing surgery, under 50 | Does not meaningfully apply — the tissue is gone. | HRT generally appropriate to around natural menopause age. Plan before surgery. |
| Personal history of breast cancer | Breast considerations dominate the decision. | Individual specialist advice. Non-hormonal options usually explored first. |
| Early menopause for any reason | Small, and weighed against real bone and cardiovascular cost of not treating. | HRT usually recommended to around natural menopause age. |
*For most women the breast cancer association with combined preparations is the more relevant of the two. Both belong in the conversation.
The evidence associates hormone therapy use with a small increase in ovarian cancer risk rather than establishing that it causes it. The distinction matters: this evidence is largely observational, so it demonstrates an association that could be partly explained by differences between women who take hormone therapy and those who do not. The association is consistent enough to mention in a discussion and to factor into a decision. It is not strong enough to make hormone therapy an unreasonable choice, particularly given that the absolute increase operates on a low baseline lifetime risk of roughly one to two per cent.
Small in absolute terms, which is the number that matters for your decision. General population lifetime ovarian cancer risk is roughly one to two per cent, so a modest relative increase applied to that produces a modest absolute increase — best understood as a small number of additional cases across a very large number of women, rather than as a percentage. Reporting on this is dominated by relative risk, which sounds far more alarming without a baseline attached. The association also appears to weaken with time since stopping, so past use carries less weight than current use.
For most women in this position without a personal history of breast cancer, yes, and it is generally considered appropriate up to around the average age of natural menopause. Two points make this different from the general discussion. First, you are replacing hormones your body would still have been producing rather than adding hormones beyond the normal span — removing the ovaries at 38 brings menopause forward by more than a decade, with real consequences for bone and cardiovascular health if untreated. Second, it cannot meaningfully raise ovarian cancer risk, because the tissue at risk has been removed.
Not on the strength of reading about it — that is precisely the decision that causes avoidable harm. Menopausal symptoms are real and treatable, untreated bone loss has consequences, and a great many women stop hormone therapy on a headline and spend years worse off for it. If you are concerned, book a review rather than stopping abruptly. The useful conversation covers your actual baseline risk, whether family history changes it, whether your symptoms could be managed with local treatment instead, and whether the breast association is more relevant to your situation than the ovarian one.
No, and this distinction is worth knowing because it resolves the question entirely for many women. Local vaginal oestrogen treats vaginal dryness, discomfort during intercourse and associated urinary symptoms, and it involves minimal systemic absorption — so most of the systemic risk discussion around hormone therapy simply does not apply to it. A great many women endure these symptoms for years, either assuming nothing can be done or having read warnings about systemic hormone therapy that were never relevant to the local preparations. If your troublesome symptoms are vaginal, raise this specifically.
For many women, yes, particularly with combined preparations containing a progestogen and particularly for BRCA carriers. Women frequently arrive concerned about the ovarian association when the breast association is the more relevant consideration for their situation. This is not a reason to avoid hormone therapy — it is a reason to have the conversation properly rather than focusing on whichever risk you happened to read about first. A good discussion covers both associations alongside the substantial benefits, and reaches an actual decision rather than leaving you with vague unease.
The first consultation is free and runs to about 45 minutes. What is usually most useful is not a risk figure but the context around it — your actual baseline, whether family history changes it, whether your symptoms are systemic or local, and whether the breast association matters more for you than the ovarian one. Genetic counselling and BRCA and HRD testing are delivered in-house at CION where family history is part of the question. Risk-reducing and gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there.